# 510(k) Summary K070005 (Summary of Safety and Effectiveness)

# Submitted by:

Instrumentation Laboratory Company   
113 Hartwell Avenue   
Lexington, MA 02421

# Contact Person:

Carol Marble, Regulatory Affairs Director Phone No.: 781-861-4467 Fax No.: 781-861-4207

Prepared: June 28, 2007

# Device Name:

HemosIL RecombiPlasTin 2G

# Regulatory Information:

864.7750 Prothrombin Time Test Class Ⅱ   
81GJS Test, Time, Prothrombin   
864.7340 Fibrinogen Determination System Class II   
81GIS Test, Fibrinogen

# Predicate Device:

K043184 HemosIL RecombiPlasTin

# Device Description:

The RecombiPlasTin 2G reagent is formulated to be insensitive to therapeutic levels of heparin. In the PT test, the addition of the tissue thromboplastin (RecombiPlasTin 2G reagent) to the patient plasma in the presence of calcium ions initiates the activation of the extrinsic pathway. This results ultimately in the conversion of fibrinogen to fibrin, with formation of a solid gel. For the IL Coagulation Systems only, the Fibrinogen is quantitated (PT-based method) by relating the absorbance or light-scatter during clotting to a calibrator.

# Device Intended Use:

HemosIL RecombiPlasTin 2G is a high sensitivity thromboplastin reagent based on recombinant human tissue factor (RTF) for the quantitative determination in human citrated plasma of Prothrombin Time (PT) on IL Coagulation and ELECTRA Systems and Fibrinogen on IL Coagulation Systems only.

The product is used for the evaluation of the extrinsic coagulation pathway and the monitoring of Oral Anticoagulant Therapy (OAT).

# Statement of Technological Characteristics of the Device Compared to Predicate Device:

The performance of HemosIL RecombiPlasTin 2G with a modified phospholipid ratio is not materially different from the FDA cleared device: HemosIL RecombiPlasTin (K043184).

# 510(k) Summary (Cont.)

# Summary of Performance Data:

# Precision

Within run and total precision assessed over multiple runs using three levels of control plasma for PT and two levels of control plasma for fibrinogen gave the following results:

<table><tr><td>ELECTRA</td><td>Mean (PT seconds)</td><td>CV % (Within run) CV % (Total)</td><td></td></tr><tr><td>Normal</td><td>12.2</td><td>1.3</td><td>1.9</td></tr><tr><td>Low Abnormal</td><td>21.1</td><td>1.2</td><td>2.6</td></tr><tr><td>High Abnormal</td><td>31.3</td><td>1.3</td><td>3.4</td></tr><tr><td>ACL Family</td><td>Mean (PT seconds)</td><td>CV % (Within run)</td><td>CV % (Total)</td></tr><tr><td>Normal</td><td>11.7</td><td>0.6</td><td>1.5</td></tr><tr><td>Low Abnormal</td><td>21.6</td><td>1.0</td><td>1.9</td></tr><tr><td>High Abnormal</td><td>32.9</td><td>1.1</td><td>2.6</td></tr><tr><td>ACL Futura/ACL Advance Mean (PT seconds)</td><td></td><td>CV % (Within run)</td><td>CV % (Total)</td></tr><tr><td>Normal</td><td>12.5</td><td>1.1</td><td>1.9</td></tr><tr><td>Low Abnormal</td><td>23.8</td><td>1.6</td><td>1.9</td></tr><tr><td>High Abnormal</td><td>36.0</td><td>1.8</td><td>2.4</td></tr><tr><td>ACL TOP</td><td>Mean (PT seconds)</td><td>CV % (Within run)</td><td>) CV % (Total)</td></tr><tr><td>Normal</td><td>11.9</td><td>0.8</td><td>2.2</td></tr><tr><td>Low Abnormal</td><td>22.0</td><td>0.8</td><td>3.1</td></tr><tr><td>High Abnormal</td><td>34.0</td><td>0.9</td><td>3.1</td></tr><tr><td>ACL Family</td><td>Mean (Fibrinogen mg/dL) CV % (Within run) CV % (Total)</td><td></td><td></td></tr><tr><td>Normal</td><td>319</td><td>4.2</td><td>5.0</td></tr><tr><td>Low Fibrinogen Control</td><td>149</td><td>5.9</td><td>6.9</td></tr><tr><td>ACL Futura/ ACL Advance</td><td>Mean (Fibrinogen mg/dL) CV % (Within run) CV % (Total)</td><td></td><td></td></tr><tr><td>Normal</td><td>229</td><td>3.0</td><td>3.1</td></tr><tr><td>Low Fibrinogen Control</td><td>157</td><td>3.7</td><td>4.5</td></tr><tr><td>ACL TOP</td><td>Mean (Fibrinogen mg/dL) CV % (Within run)</td><td></td><td>CV % (Total)</td></tr><tr><td>Normal</td><td>296</td><td>1.4</td><td>2.4</td></tr><tr><td>Low Fibrinogen Control</td><td>135</td><td>2.9</td><td>3.6</td></tr></table>

# 510(k) Summary (Cont.)

# Summary of Performance Data (Cont.):

# Method Comparison - In-house

An in-house method comparison study was performed with modified RecombiPlasTin 2G versus the current HemosIL RecombiPlasTin:

<table><tr><td rowspan=1 colspan=1>System</td><td rowspan=1 colspan=1>Assay</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>r</td><td rowspan=1 colspan=1>Reference Method</td></tr><tr><td rowspan=4 colspan=1>ELECTRAACL FamilyACL Futura/ACL AdvanceACL TOP</td><td rowspan=4 colspan=1>PT(Seconds)</td><td rowspan=1 colspan=1>0.7637</td><td rowspan=1 colspan=1>3.0427</td><td rowspan=1 colspan=1>0.9789</td><td rowspan=1 colspan=1>HemosIL RTF on ELECTRA</td></tr><tr><td rowspan=1 colspan=1>0.7910</td><td rowspan=1 colspan=1>2.7860</td><td rowspan=1 colspan=1>0.9885</td><td rowspan=1 colspan=1>HemosIL RTFon ACL Family</td></tr><tr><td rowspan=1 colspan=1>0.8075</td><td rowspan=1 colspan=1>2.8899</td><td rowspan=1 colspan=1>0.9913</td><td rowspan=1 colspan=1>HemosIL RTFFon ACL Advance</td></tr><tr><td rowspan=1 colspan=1>0.8010</td><td rowspan=1 colspan=1>2.7138</td><td rowspan=1 colspan=1>0.9916</td><td rowspan=1 colspan=1>HemosIL RTF on ACL TOP</td></tr><tr><td rowspan=3 colspan=1>ACL FamilyACL Futura/ACL AdvanceACL TOP</td><td rowspan=3 colspan=1>Fibrinogen(mg/dL)</td><td rowspan=1 colspan=1>0.9350</td><td rowspan=1 colspan=1>6.1043</td><td rowspan=1 colspan=1>0.9866</td><td rowspan=1 colspan=1>Fibrinogen (PT-Fib based) onACL Family</td></tr><tr><td rowspan=1 colspan=1>0.9711</td><td rowspan=1 colspan=1>10.933</td><td rowspan=1 colspan=1>0.9783</td><td rowspan=1 colspan=1>Fibrinogen (PT-Fib based) onACL Advance</td></tr><tr><td rowspan=1 colspan=1>1.0129</td><td rowspan=1 colspan=1>-3.6298</td><td rowspan=1 colspan=1>0.9969</td><td rowspan=1 colspan=1>Fibrinogen (PT-Fib based) onACL TOP</td></tr></table>

# Method Comparison - Field Site

Two field site method comparison studies were performed with modified RecombiPlasTin 2G versus the current HemosIL RecombiPlasTin:

<table><tr><td rowspan=1 colspan=1>System</td><td rowspan=1 colspan=1>Assay</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>r</td><td rowspan=1 colspan=1>Reference Method</td></tr><tr><td rowspan=3 colspan=1>ACL TOP</td><td rowspan=1 colspan=1>PT (Sec.)</td><td rowspan=1 colspan=1>0.8137</td><td rowspan=1 colspan=1>4.0035</td><td rowspan=1 colspan=1>0.9934</td><td rowspan=3 colspan=1>HemosIL RTF on ACL TOP</td></tr><tr><td rowspan=1 colspan=1>PT INR</td><td rowspan=1 colspan=1>1.0838</td><td rowspan=1 colspan=1>-0.1071</td><td rowspan=1 colspan=1>0.9945</td></tr><tr><td rowspan=1 colspan=1>Fibrinogen(mg/dL)</td><td rowspan=1 colspan=1>0.9805</td><td rowspan=1 colspan=1>5.3466</td><td rowspan=1 colspan=1>0.9946</td></tr><tr><td rowspan=1 colspan=1>System</td><td rowspan=1 colspan=1>Assay</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>r</td><td rowspan=1 colspan=1>Reference Method</td></tr><tr><td rowspan=3 colspan=1>ACL 10000</td><td rowspan=1 colspan=1>PT (Sec.)</td><td rowspan=1 colspan=1>0.7935</td><td rowspan=1 colspan=1>2.1733</td><td rowspan=1 colspan=1>0.9887</td><td rowspan=3 colspan=1>HemosIL RTF on ACL 10000</td></tr><tr><td rowspan=1 colspan=1>PT INR</td><td rowspan=1 colspan=1>0.9446</td><td rowspan=1 colspan=1>0.0367</td><td rowspan=1 colspan=1>0.9881</td></tr><tr><td rowspan=1 colspan=1>Fibrinogen(mg/dL)</td><td rowspan=1 colspan=1>0.9431</td><td rowspan=1 colspan=1>7.5763</td><td rowspan=1 colspan=1>0.9832</td></tr></table>

# Expected Values

A normal range study was performed using the modified RecombiPlasTin 2G reagent:

<table><tr><td rowspan=1 colspan=1>PT</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Range</td></tr><tr><td rowspan=1 colspan=1>ELECTRA</td><td rowspan=1 colspan=1>130</td><td rowspan=1 colspan=1>9.8 - 12.2 (seconds)</td></tr><tr><td rowspan=1 colspan=1>•  ACL Family</td><td rowspan=1 colspan=1>130</td><td rowspan=1 colspan=1>9.1 - 12.1 (seconds)</td></tr><tr><td rowspan=1 colspan=1>•  ACL Futura/ACL Advance</td><td rowspan=1 colspan=1>130</td><td rowspan=1 colspan=1>9.9 - 12.9 (seconds)</td></tr><tr><td rowspan=1 colspan=1>• ACL TOP</td><td rowspan=1 colspan=1>130</td><td rowspan=1 colspan=1>9.4 - 12.5 (seconds)</td></tr><tr><td rowspan=1 colspan=1>Fibrinogen</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Range</td></tr><tr><td rowspan=1 colspan=1>• ACL Family</td><td rowspan=1 colspan=1>129</td><td rowspan=1 colspan=1>308 - 613 (mg/dL)</td></tr><tr><td rowspan=1 colspan=1>•  ACL Futura/ACL Advance</td><td rowspan=1 colspan=1>129</td><td rowspan=1 colspan=1>222 - 340 (mg/dL)</td></tr><tr><td rowspan=1 colspan=1>•  ACL TOP</td><td rowspan=1 colspan=1>129</td><td rowspan=1 colspan=1>276 - 471 (mg/dL)</td></tr></table>

\*NOTE: The product insert advises customers that "These results were obtained using a specific lot of reagent. Due to many variables which may affect clotting times, each laboratory should establish its own normal range."

# 510(k) Summary (Cont.) (Summary of Safety and Effectiveness)

# Summary of Performance Data (Cont.):

# CUBICIN (Daptomycin for injection) Dose-Response Testing

An in vitro study indicated no clinically significant CUBICIN (Daptomycin for injection) dose response with the modified HemosIL RecombiPlasTin 2G using the following specifications:

NOTE: The expected peak dosing for CUBICIN (Daptomycin for injection) in circulating blood is $7 5 \mu \mathrm { g / m L }$ . Normal Sample $\pm \nobreakspace 1 \nobreakspace$ second from unspiked sample Coumadin Sample $\pm 1 0 \%$ recovery of the unspiked sample

Data from this testing on representative IL Coagulation Systems are provided below:

<table><tr><td rowspan=1 colspan=5>ACL 6000 Coagulation Analyzer</td></tr><tr><td rowspan=1 colspan=1>CUBICINConcentration(μg/mL)</td><td rowspan=1 colspan=1>Normal Sample(PT Seconds)</td><td rowspan=1 colspan=1>Change inSeconds</td><td rowspan=1 colspan=1>Coumadin Sample(PT Seconds)</td><td rowspan=1 colspan=1>% Recovery</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10.5</td><td rowspan=1 colspan=1>**</td><td rowspan=1 colspan=1>22.5</td><td rowspan=1 colspan=1>--</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>10.5</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>22.7</td><td rowspan=1 colspan=1>101%</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10.6</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>23.0</td><td rowspan=1 colspan=1>102%</td></tr><tr><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>10.5</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>23.4</td><td rowspan=1 colspan=1>104%</td></tr><tr><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>10.6</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>24.0</td><td rowspan=1 colspan=1>107%</td></tr><tr><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>10.9</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>24.8</td><td rowspan=1 colspan=1>110%</td></tr><tr><td rowspan=1 colspan=1>125</td><td rowspan=1 colspan=1>11.0</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>24.7</td><td rowspan=1 colspan=1>110%</td></tr></table>

ACL 10000 Coagulation Analyzer   

<table><tr><td rowspan=1 colspan=5>RCL Tovoo Coagulatloll Allalyzel</td></tr><tr><td rowspan=1 colspan=1>CUBICINConcentration(μg/mL)</td><td rowspan=1 colspan=1>Normal Sample(PT Seconds)</td><td rowspan=1 colspan=1>Change inSeconds</td><td rowspan=1 colspan=1>Coumadin Sample(PT Seconds)</td><td rowspan=1 colspan=1>% Recovery</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>11.7</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>25.1</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>11.7</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>25.3</td><td rowspan=1 colspan=1>101%</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>11.8</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>25.7</td><td rowspan=1 colspan=1>102%</td></tr><tr><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>11.9</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>25.9</td><td rowspan=1 colspan=1>103%</td></tr><tr><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>12.0</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>26.4</td><td rowspan=1 colspan=1>105%</td></tr><tr><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>12.4</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>26.9</td><td rowspan=1 colspan=1>107%</td></tr><tr><td rowspan=1 colspan=1>125</td><td rowspan=1 colspan=1>12.4</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>27.5</td><td rowspan=1 colspan=1>110%</td></tr></table>

# 510(k) Summary (Cont.) (Summary of Safety and Effectiveness)

# Summary of Performance Data (Cont.):

CUBICIN (Daptomycin for injection) Dose-Response Testing (Cont.)

<table><tr><td rowspan=1 colspan=5>ACL Advance Coagulation Analyzer</td></tr><tr><td rowspan=1 colspan=1>CUBICINConcentration(μg/mL)</td><td rowspan=1 colspan=1>Normal Sample(PT Seconds)</td><td rowspan=1 colspan=1>Change inSeconds</td><td rowspan=1 colspan=1>Coumadin Sample(PT Seconds)</td><td rowspan=1 colspan=1>% Recovery</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>12.7</td><td rowspan=1 colspan=1>--</td><td rowspan=1 colspan=1>26.9</td><td rowspan=1 colspan=1>--</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>12.8</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>26.8</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>12.6</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>27.6</td><td rowspan=1 colspan=1>103%</td></tr><tr><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>12.8</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>27.3</td><td rowspan=1 colspan=1>101%</td></tr><tr><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>12.8</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>28.4</td><td rowspan=1 colspan=1>106%</td></tr><tr><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>13.2</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>29.2</td><td rowspan=1 colspan=1>109%</td></tr><tr><td rowspan=1 colspan=1>125</td><td rowspan=1 colspan=1>13.2</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>29.5</td><td rowspan=1 colspan=1>110%</td></tr></table>

<table><tr><td rowspan=1 colspan=5>ACL TOP Coagulation Analyzer</td></tr><tr><td rowspan=1 colspan=1>CUBICINConcentration(μg/mL)</td><td rowspan=1 colspan=1>Normal Sample(PT Seconds)</td><td rowspan=1 colspan=1>Change inSeconds</td><td rowspan=1 colspan=1>Coumadin Sample(PT Seconds)</td><td rowspan=1 colspan=1>% Recovery</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>12.3</td><td rowspan=1 colspan=1>--</td><td rowspan=1 colspan=1>27.3</td><td rowspan=1 colspan=1>--</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>12.3</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>27.4</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>12.3</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>27.8</td><td rowspan=1 colspan=1>102%</td></tr><tr><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>12.5</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>27.8</td><td rowspan=1 colspan=1>102%</td></tr><tr><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>12.6</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>28.4</td><td rowspan=1 colspan=1>104%</td></tr><tr><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>12.8</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>29.3</td><td rowspan=1 colspan=1>107%</td></tr><tr><td rowspan=1 colspan=1>125</td><td rowspan=1 colspan=1>12.9</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>29.7</td><td rowspan=1 colspan=1>109%</td></tr></table>

ELECTRA 1600C Coagulation Analyzer   

<table><tr><td rowspan=1 colspan=1>CUBICINConcentration(μg/mL)</td><td rowspan=1 colspan=1>Normal Sample(PT Seconds)</td><td rowspan=1 colspan=1>Change inSeconds</td><td rowspan=1 colspan=1>Coumadin Sample(PT Seconds)</td><td rowspan=1 colspan=1>% Recovery</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>12.2</td><td rowspan=1 colspan=1>--</td><td rowspan=1 colspan=1>23.1</td><td rowspan=1 colspan=1>--</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>12.4</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>23.6</td><td rowspan=1 colspan=1>102%</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>12.3</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>22.0</td><td rowspan=1 colspan=1>95%</td></tr><tr><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>12.6</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>24.0</td><td rowspan=1 colspan=1>104%</td></tr><tr><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>12.4</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>24.2</td><td rowspan=1 colspan=1>105%</td></tr><tr><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>12.8</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>23.4</td><td rowspan=1 colspan=1>101%</td></tr><tr><td rowspan=1 colspan=1>125</td><td rowspan=1 colspan=1>12.7</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>24.6</td><td rowspan=1 colspan=1>106%</td></tr></table>

# AUG 15 2007

Carol Marble   
Regulatory Affairs Director   
Instrumentation Laboratory Company   
113 Hartwell Avenue   
Lexington, Massachusetts 02421

Re: k070005 Trade/Device Name: HemosIL RecombiPlasTin 2G Regulation Number: 21 CFR 864.7750 Regulation Name: Prothrombin Time Test Regulatory Class: Class I Product Code: GJS, GIS Dated: March 22, 2007 Received: March 23, 2007

Dear Ms. Marble:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class II (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket

notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

ebetBeoderf

"Robert L. Becker, Jr., MD, PhD   
Director   
Division of Immunology and Hematology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and   
Radiological Health

# Indications for Use Statement

510(k) Number (if known): K070005

Device Name: HemosIL RecombiPlasTin 2G

# Indications for Use:

A high sensitivity thromboplastin reagent based on recombinant human tissue factor (RTF) for the quantitative in vitro diagnostic determination in human citrated plasma of Prothrombin Time (PT) on IL Coagulation and ELECTRA Systems and Fibrinogen on IL Coagulation Systems only.

The product is used for the evaluation of the extrinsic coagulation pathway and the monitoring of Oral Anticoagulant Therapy (OAT).

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD) Divisiion Sen0 ughenr Santdi Office of In Vitro Diagnostic Device Evaluation and Safety 510(k) K 070005